Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

被引：1

作者：

Tomita, Naoto ^{[1
]}

Takasaki, Hirotaka ^{[2
]}

Fujisawa, Shin ^{[3
]}

Miyashita, Kazuho ^{[4
]}

Ogusa, Eriko ^{[5
]}

Kishimoto, Kumiko ^{[6
]}

Matsuura, Shiro ^{[7
]}

Sakai, Rika ^{[2
]}

Koharazawa, Hideyuki

Yamamoto, Wataru ^{[2
]}

Fujimaki, Katsumichi ^{[4
]}

Fujita, Hiroyuki

Ishii, Yoshimi ^{[2
]}

Taguchi, Jun ^{[5
]}

Kuwabara, Hideyuki ^{[3
]}

Motomura, Shigeki ^{[2
]}

Ishigatsubo, Yoshiaki ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa, Japan

[2] Kanagawa Canc Ctr, Dept Med Oncol, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Med Ctr, Dept Med Oncol, Yokohama, Kanagawa, Japan

[4] Fujisawa City Hosp, Dept Hematology Immunol, Fujisawa, Kanagawa, Japan

[5] Shizuoka Red Cross Hosp, Dept Hematol, Shizuoka, Japan

[6] Yokosuka City Hosp, Dept Hematol, Yokosuka, Kanagawa, Japan

[7] Yamato Municipal Hosp, Dept Hematol, Yamato, Japan

来源：

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2013年 / 53卷 / 02期

关键词：

diffuse large B-cell lymphoma; follicular lymphoma; R-CHOP;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The introduction of rituximab (R) has measurably improved the outcome of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). To evaluate the outcome of patients with FL and DLBCL under R plus CHOP therapy, we performed a retrospective analysis in Yokohama City University Hematology Group in Japan. Five hundred and twenty-six patients (158, FL; 368, DLBCL) were scheduled to undergo primary therapy with 6 cycles of full-dose R-CHOP therapy with curative intent. The median observation periods in livingpa tients with FL and DLBCL were 45 months and 43 months, respectively. The complete response, 5-year progression-free survival (PFS), and 5-year overall survival (OS) rates were 86%, 50%, and 92% in the FL group, and 89%, 72%, and 80% in the DLBCL group, respectively. Although PFS was significantly better in the DLBCL group than in the FL group, OS was significantly better in FL patients. We also found that the OS and PFS of grade 3 FL patients were not statistically different from those with grade 1-2. These findings indicate that all grades of FL should be categorized simply as "FL" with regard to R-CHOP therapy. Our results also demonstrate the incurability of FL (grade 1-3B), even with R-CHOP therapy.

引用

页码：121 / 125

页数：5

共 13 条

[1] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[2] The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome [J].

Buske, Christian ;

Hoster, Eva ;

Dreyling, Martin ;

Hasford, Joerg ;

Unterhalt, Michael ;

Hiddemann, Wolfgang .

BLOOD, 2006, 108 (05) :1504-1508

[3] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[4] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[5] Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) [J].

Mounier, N ;

Briere, J ;

Gisselbrecht, C ;

Emile, JF ;

Lederlin, P ;

Sebban, C ;

Berger, F ;

Bosly, A ;

Morel, P ;

Tilly, H ;

Bouabdallah, R ;

Reyes, F ;

Gaulard, P ;

Coiffier, B .

BLOOD, 2003, 101 (11) :4279-4284

[6] CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J].

Pfreundschuh, Michael ;

Trumper, Lorenz ;

Osterborg, Anders ;

Pettengell, Ruth ;

Trneny, Marek ;

Imrie, Kevin ;

Ma, David ;

Gill, Devinder ;

Walewski, Jan ;

Zinzani, Pier-Luigi ;

Stahel, Rolf ;

Kvaloy, Stein ;

Shpilberg, Ofer ;

Jaeger, Ulrich ;

Hansen, Mads ;

Lehtinen, Tuula ;

Lopez-Guillermo, Armando ;

Corrado, Claudia ;

Scheliga, Adriana ;

Milpied, Noel ;

Mendila, Myriam ;

Rashford, Michelle ;

Kuhnt, Evelyn ;

Loeffler, Markus .

LANCET ONCOLOGY, 2006, 7 (05) :379-391

[7] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J].

Sehn, Laurie H. ;

Berry, Brian ;

Chhanabhai, Mukesh ;

Fitzgerald, Catherine ;

Gill, Karamjit ;

Hoskins, Paul ;

Klasa, Richard ;

Savage, Kerry J. ;

Shenkier, Tamara ;

Sutherland, Judy ;

Gascoyne, Randy D. ;

Connors, Joseph M. .

BLOOD, 2007, 109 (05) :1857-1861

[8] A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].

SHIPP, MA ;

HARRINGTON, DP ;

ANDERSON, JR ;

ARMITAGE, JO ;

BONADONNA, G ;

BRITTINGER, G ;

CABANILLAS, F ;

CANELLOS, GP ;

COIFFIER, B ;

CONNORS, JM ;

COWAN, RA ;

CROWTHER, D ;

DAHLBERG, S ;

ENGELHARD, M ;

FISHER, RI ;

GISSELBRECHT, C ;

HORNING, SJ ;

LEPAGE, E ;

LISTER, TA ;

MEERWALDT, JH ;

MONTSERRAT, E ;

NISSEN, NI ;

OKEN, MM ;

PETERSON, BA ;

TONDINI, C ;

VELASQUEZ, WA ;

YEAP, BY .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994

[9] Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy [J].

Shustik, J. ;

Quinn, M. ;

Connors, J. M. ;

Gascoyne, R. D. ;

Skinnider, B. ;

Sehn, L. H. .

ANNALS OF ONCOLOGY, 2011, 22 (05) :1164-1169

[10] Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP [J].

Shustik, Jesse ;

Han, Guangming ;

Farinha, Pedro ;

Johnson, Nathalie A. ;

Neriah, Susana Ben ;

Connors, Joseph M. ;

Sehn, Laurie H. ;

Horsman, Douglas E. ;

Gascoyne, Randy D. ;

Steidl, Christian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (01) :96-101

← 1 2 →